TNF and rheumatoid arthritis: Subsequently, results from the EARTH EXPLORER 2 trial confirmed that mavrilimumab was efficacious and well‐tolerated in RA patients who were inadequate responders to both conventional DMARDs and TNF‐inhibitors 108.